Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TIM-3+ CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignancies.
Minnie SA, Waltner OG, Zhang P, Takahashi S, Nemychenkov NS, Ensbey KS, Schmidt CR, Legg SRW, Comstock M, Boiko JR, Nelson E, Bhise SS, Wilkens AB, Koyama M, Dhodapkar MV, Chesi M, Riddell SR, Green DJ, Spencer A, Furlan SN, Hill GR. Minnie SA, et al. Among authors: spencer a. Sci Immunol. 2024 Apr 19;9(94):eadg1094. doi: 10.1126/sciimmunol.adg1094. Epub 2024 Apr 19. Sci Immunol. 2024. PMID: 38640253 Free PMC article.
Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity.
Minnie SA, Waltner OG, Ensbey KS, Nemychenkov NS, Schmidt CR, Bhise SS, Legg SRW, Campoy G, Samson LD, Kuns RD, Zhou T, Huck JD, Vuckovic S, Zamora D, Yeh A, Spencer A, Koyama M, Markey KA, Lane SW, Boeckh M, Ring AM, Furlan SN, Hill GR. Minnie SA, et al. Among authors: spencer a. Sci Immunol. 2022 Oct 21;7(76):eabo3420. doi: 10.1126/sciimmunol.abo3420. Epub 2022 Oct 14. Sci Immunol. 2022. PMID: 36240285 Free PMC article.
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.
Minnie SA, Waltner OG, Ensbey KS, Olver SD, Collinge AD, Sester DP, Schmidt CR, Legg SR, Takahashi S, Nemychenkov NS, Sekiguchi T, Driessens G, Zhang P, Koyama M, Spencer A, Holmberg LA, Furlan SN, Varelias A, Hill GR. Minnie SA, et al. Among authors: spencer a. J Clin Invest. 2023 Feb 15;133(4):e157907. doi: 10.1172/JCI157907. J Clin Invest. 2023. PMID: 36512425 Free PMC article.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL. Holstein SA, et al. Among authors: spencer a. Biol Blood Marrow Transplant. 2020 Oct;26(10):e247-e255. doi: 10.1016/j.bbmt.2020.06.011. Epub 2020 Jun 24. Biol Blood Marrow Transplant. 2020. PMID: 32589921 Free PMC article. Review.
Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma.
Mithraprabhu S, Kalff A, Gartlan KH, Savvidou I, Khong T, Ramachandran M, Cooke RE, Bowen K, Hill GR, Reynolds J, Spencer A. Mithraprabhu S, et al. Among authors: spencer a. Br J Haematol. 2021 Apr;193(1):160-170. doi: 10.1111/bjh.17080. Epub 2020 Sep 18. Br J Haematol. 2021. PMID: 32945549 Free PMC article. Clinical Trial.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. Among authors: spencer a. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Targeting MCL-1 in hematologic malignancies: Rationale and progress.
Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, Caenepeel S, Hughes P, McIver Z, Mezzi K, Morrow PK, Stein A. Wei AH, et al. Among authors: spencer a. Blood Rev. 2020 Nov;44:100672. doi: 10.1016/j.blre.2020.100672. Epub 2020 Feb 21. Blood Rev. 2020. PMID: 32204955 Free PMC article. Review.
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Liu H, Hu Y, Rimoldi R, Von Hagt C, Khong EWC, Lee N, Flemming S, Spencer A, Dear AE. Liu H, et al. Among authors: spencer a. Oncol Lett. 2019 Feb;17(2):2543-2550. doi: 10.3892/ol.2018.9841. Epub 2018 Dec 17. Oncol Lett. 2019. PMID: 30675316 Free PMC article.
1,617 results